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We compared the neutralization abilities of individual monoclonal antibodies (MAb) of two large panels reactive with L1 epitopes of HPV-11
or HPV-16. Binding titers were compared using both L1-only VLPs and L1/L2 pseudovirions. While the VLPs were antigenically similar to the
pseudovirions, clear differences in the surface exposure of some epitopes were evident with the HPV-16 particles. To determine whether all
antibody binding events are equivalent in their neutralizing effect on infectious HPV virions or pseudovirions, the binding and neutralization titers
for individual MAbs were used to calculate the relative neutralization efficiency for each antibody. HPV neutralization was achieved by all MAbs
capable of strong binding to either linear or conformation-sensitive epitopes on pseudovirus particles. Our data suggest, however, that some L1
epitopes may be more neutralization-sensitive than other surface epitopes, in that successful infection can be blocked by varying degrees of
epitope saturation. Additionally, the effective neutralization of virions by several monovalent Fab fragments and single-chain variable fragments
(scFv) demonstrates that viral neutralization does not require HPV particle aggregation or L1 crosslinking. Identification of capsid protein
structures rich in neutralization-sensitive epitopes may aid in the development of improved recombinant vaccines capable of eliciting effective and
long-term antibody-mediated protection against multiple HPV types.
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epitopes; Vaccine; Pseudovirus; Virus like particles (VLPs)Introduction
Human papillomaviruses (HPVs) are implicated as the
etiological agent in most anogenital cancers and in a subset of
head and neck cancers. Considerable effort has been expended
in recent years on the development of prophylactic vaccines to
induce protective antibody-mediated immunity to multiple HPV
types. Recent clinical trials have demonstrated that immuniza-
tion with virus-like particles (VLPs) can produce significant
protection from infection by vaccine-specific HPV types
(Harper et al., 2004; Koutsky et al., 2002; Villa et al., 2005).
Because over a dozen “high risk” HPV genotypes are
commonly associated with cervical cancers worldwide with
significant geographic variation, the development of vaccines⁎ Corresponding author.
E-mail address: ndc1@psu.edu (N.D. Christensen).
0042-6822/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2006.12.002protecting against multiple HPV types is a public health priority
(Munoz et al., 2004).
Papillomaviruses have nonenveloped capsids composed of
two proteins, L1 and L2. L1 is the major capsid protein
contributing about 85% of the weight of the capsid. L1
molecules from closely related HPV species share several
highly homologous domains separated by four or more
hypervariable regions. The majority of the hypervariable
regions of L1 form loops extending outward from the surface
of the capsid (Chen et al., 2000). Intertypic hybrid VLPs have
been successfully assembled from L1 proteins that possess loop
substitutions belonging to different HPV genotypes (Carter et
al., 2003, 2006; Christensen et al., 2002; Olcese et al., 2004).
Serological studies have demonstrated that HPV capsids
contain neutralizing epitopes that are highly type specific,
generally conformation-dependent, and involving the hyper-
variable loops (Christensen et al., 1990; Pastrana et al., 2004).
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capsid, immunodominance is evident in the humoral response
(Wang et al., 1997) and can be maintained in the context of
hybrid VLPs (Christensen et al., 2002). Cross-reactive MAbs
targeting conserved linear (conformation-insensitive) L1 epi-
topes have been identified, but these antibodies are generally
believed to have relatively poor neutralization titers (Christen-
sen et al., 1996b; Combita et al., 2002).
Studies using other virus systems have been performed to
evaluate the relative neutralization efficiencies of different MAbs,
Fab fragments, or single-chain variable fragments (scFv)
(Edwards and Dimmock, 2000; Moore et al., 1995; Schofield et
al., 1997; Yuan and Parrish, 2000). A limited number of studies
have been described comparing the neutralizing efficiencies of
intact MAbs targeting HPV capsids (Christensen et al., 1996b;
Combita et al., 2002; Roden et al., 1997). Several questions
remain after these previous studies. First, might the inability of
some L1-targeting MAbs to neutralize virions be overcome by
higher antibody concentrations? Second, are differences between
neutralizing efficiencies solely a function of the unique MAbs
themselves, or do the structural locations of the epitopes contribute
to the potency of their interaction with the capsid? Additionally, it
is unknownwhether antibody-mediated neutralization requires the
crosslinking of L1 molecules/virions or whether monovalent
binding events by Fab fragments and scFv can also neutralize
HPV virions, as has been shown with other virus models.
L1 VLP vaccines contain immunodominant epitopes and
may also include non-neutralizing epitopes. If virus neutraliza-
tion occurs more efficiently (i.e. with a lower degree of epitope
saturation) by antibody binding events at particular locations on
the capsid, vaccine efficacy may be improved by the removal of
non-neutralizing epitopes or those which bias the humoral
response unfavorably toward epitopes of limited importance
and away from epitopes critical to viral adsorption, and entry
(Cleveland et al., 2000).Table 1
Neutralization efficiencies for L1-targeting MAbs reactive with HPV-11
MAb Location of the
targeted epitope a
Isotype Half-max binding
concentration
(nM) (VLPs)
Half-max bi
concentratio
(nM) (psV)
H6.C6 N-term linear site IgG2a 2.2±0.7 15±6
H6.I2 N-term linear site IgM 2.3±0.1 5.0±0.0
H6.E51 N-term linear site IgG1 3.2±0.9 5.6±0.5
H11.A3.2 BC? and FG? IgG2a 0.78±0.18 0.39±0.00
H11.B2 DE IgG2b 0.38±0.09 0.18±0.08
H11.F1 DE IgG2a 0.35±0.07 0.10±0.02
H11.G5 DE IgG2a 1.5±0.2 1.1±0.0
H11.H3 HI IgG2b 0.19±0.05 0.067±0.026
G131S.C2 Unknown IgG1 12±8 5.4±1.0
G131S.C3 FG and HI IgM 3.2±0.4 0.66±0.12
G131S.I1 FG (HI) IgG1 0.77±0.54 0.22±0.05
NT = not tested.
a Epitopes were mapped in previous studies—see Materials and methods section. L
the loop influences the conformation of the MAb's epitope without directly interac
b Calculated using the half-maximal binding concentrations determined using pseu
The neutralization efficiency ratio for each MAb is defined in Formula #1 as the q
c Normalized to G131S.I1 for ease of comparison. Higher efficiency ratios indicate
with a lesser degree of epitope saturation as determined by binding affinity.We utilized MAbs, Fab fragments, and scFv reactive with
HPV-11 or HPV-16 particles to test the hypothesis that binding
events at all L1 surface epitopes are equivalent in neutralizing
infectious particles. Our results indicate that, while all MAb-L1
binding events can successfully block viral infection, antibody–
capsid interaction at a subset of L1 epitopes can result in virus
neutralization with a lower degree of epitope saturation. Addi-
tionally, while our data are consistent with the assumption that
particle aggregation is a potential mechanism of HPV neutra-
lization, we are the first to demonstrate that monovalent Fab
fragments and scFv can effectively neutralizeHPVvirions. These
studies may prove useful in future structural studies, vaccine
design, and in the investigation of early virus–cell interactions.
Results
Neutralization efficiencies of HPV-11 reactive MAbs
We used an existing panel of MAbs binding specifically to
conformation-sensitive epitopes of HPV-11 L1 (Table 1). Three
cross-reactive MAbs generated against HPV-6b were also
included which bind linear epitopes in the first 88 amino
acids of L1. All purified MAbs were analyzed for their binding
affinities to L1-only VLPs and to L1/L2 pseudovirions. Table 1
shows that half-maximal binding concentrations for the panel
had a range of over two orders of magnitude. The entire panel
bound both VLPs and pseudovirions similarly, however,
indicating that the two particle types are antigenically similar.
The largest difference in affinity between particle types was
seen with H6.C6 (∼7-fold reduced affinity with pseudovirions),
suggesting that its targeted linear epitope on the NH2-terminus
of L1 may be less exposed on pseudovirions than on VLPs.
To compare the efficiencies of the various MAbs to interrupt
viral infection, we performed neutralization assays in which
authentic HPV-11 virions were incubated with purified MAbnding
n
Complete
neutralization
titer (nM)
Neutralization
efficiency ratio b
Normalized
to G131S.I1 c
Neutralizes
pre-attached
virions?
533 0.028 100 Yes
22 0.23 820 NT
>27,000 <0.00021 <0.75 NT
533 0.00073 2.6 Yes
4.17 0.043 150 Yes
16.7 0.0060 21 Yes
67 0.016 57 Yes
0.25 0.27 960 Yes
200 0.027 96 NT
1.11 0.59 2100 Yes
800 0.00028 1 NT
oop structures are shown in parentheses, e.g. (HI), if available data suggest that
ting with the antibody.
dovirions. Neutralization titers were determine using authentic HPV-11 virions.
uotient of half-max and neutralization titer concentrations.
the ability to completely neutralize a set number of HPV-11 particles (1.6×108)
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infected cells and assayed for viral transcripts by nested RT-
PCR (Fig. 1A). This assay is capable of detecting infections
caused by <1 virus particle per cell (Fig. 1B) (Culp and
Christensen, 2003). The absence of visible amplicons following
amplification, therefore, indicates >99% neutralization which
we will hereafter term “complete neutralization”.
In order to normalize the neutralization titer for differences in
binding affinity/avidity, we calculated a neutralization “effi-
ciency” ratio using the neutralization titer and half-maximal
binding concentration as follows.
half−max concentration nM
neutralization titer nM
¼ neutralization efficiency ratio
ð1Þ
For these experiments we assumed that pseudovirions more
accurately model authentic virions than L1-only VLPs, there-
fore the half-maximal binding concentration measured with
pseudovirions was utilized in the above calculation. This
analytical approach allowed comparisons between different
MAbs to be made in terms of the degree of epitope saturation
required for the complete neutralization of the input virus
particles. MAbs with high efficiency ratios require less
saturation of their specific epitope to achieve neutralization.
Table 1 shows that complete neutralization of HPV-11
virions can be achieved byMAbs binding to both conformation-Fig. 1. Neutralization of HPV-11 assayed by nested RT-PCR. (A) For
measurement of neutralization titers, A431 cells were infected with virions
(150 particles/cell) which had been preincubated with 2-fold dilutions of
purified MAb (H11.B2 shown as representative data). E1^E4 spliced transcripts
were amplified by nested RT-PCR 4 days following infection. All reported titers
were obtained in two independent experiments. (B) A431 cells were infected
with the indicated amounts of HPV-11 particles and infection was assayed 4
days later using nested RT-PCR targeting the E1^E4 splice junction. This
experiment demonstrates the high sensitivity of this infection assay as viral RNA
is detectable in total RNA of cells infected with fewer than 1 particle/cell.dependent and linear epitopes. Normalized to the weakest
neutralizing MAb (G131S.I1) for ease of comparison, this
analysis suggests three “tiers” of neutralizing MAbs (Fig. 2A).
When normalized for binding affinities, three antibodies
(G131S.G3, H11.H3, and H6.I2) show “potent” neutralizing
efficiencies, five antibodies (H11.B2, H6.C6, G131S.C2, H11.
G5, and H11.F1) show “intermediate” neutralizing efficiencies,
and the remaining three antibodies (H11.A3.2, G131S.I1, and
H6.E51) show relatively “weak” neutralizing efficiencies. All
antibodies except H6.E51 were able to completely neutralize
virions in this assay.
Of the three MAbs showing “potent” neutralization
efficiencies, two are isotype IgM, with one (G131S.G3)
targeting a conformation-dependent epitope involving both
the FG and HI loops of L1 and the other IgM (H6.I2) targeting
a linear epitope near the NH2-terminus. These results suggest
that aggregation of virions may be an effective mechanism of
HPV neutralization. Efforts to generate Fab and F(ab)2
fragments from G131S.G3 were unsuccessful. The only
divalent IgG antibody in this group was H11.H3 which binds
to an epitope in the HI loop. Because H11.H3 is unique in its
ability to bind equivalently to wild type HPV-11 VLPs and to
intertypic hybrid VLPs containing only the HI loop of HPV-11,
it remains untested whether other MAbs binding solely to
epitopes on the HI loop might have similarly high neutralizing
efficiencies.
All three IgG antibodies which target epitopes found on the
DE loop of L1 (H11.B2, H11.F1, and H11.G5) were
approximately equivalent in their neutralizing efficiencies,
suggesting that all binding events at this loop might yield
similar neutralization results. Additional “intermediate” effi-
ciencies were seen with G131S.C2 which binds a complex
conformation-dependent epitope influenced by both termini of
L1 (unpublished data) and for H6.C6 which binds a linear
epitope of the NH2-terminus of L1. The considerable neutraliz-
ing abilities of H6.I2 and H6.C6 demonstrate that antibodies
binding to conserved linear epitopes can be effective neutrali-
zers. Both neutralized virions with much less epitope saturation
than did G131S.I1, which binds a complex conformation-
sensitive epitope created, at least in part, by residues in the FG
loop. All tested antibodies were also able to neutralize HPV-11
preadsorbed to A431 cells demonstrating that post-attachment
events in HPV-11 infection can be interrupted by binding events
at both linear and conformation-sensitive epitopes (Table 1).
Neutralization of HPV-11 pseudovirions
We next used the same approach to compare the ability of
our HPV-11 MAb panel to neutralize pseudovirions delivering a
secreted alkaline phosphatase (seAP) expression plasmid (Buck
et al., 2004; Pastrana et al., 2004). HPV-11 pseudovirions were
preincubated with serial dilutions of the MAbs of the panel prior
to the inoculation of 293TT cells. Following the determination
of seAP levels in spent media 3 days post-infection, neutraliza-
tion titers were determined for each antibody and used with
binding affinities to determine relative neutralization efficien-
cies using Formula #1.
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shown), the mean neutralization titers at the EC50, EC90, and
EC99 levels show a similar pattern for each MAb of the panel
(Fig. 2B). By our analysis, most of the antibodies neutralized
both virions and pseudovirions with similar relative efficiencies,
for example, H6.I2, H11.B2, and H11.A3.2 were relatively
potent, intermediate, and poor neutralizers, respectively, of both
types of infectious particles (Fig. 2C). A subset of the MAbs,however, had different relative neutralization efficiencies when
compared to those calculated for the neutralization of virions.
Most notably, while G131S.G3, H11.H3, and H6.C6 were each
efficient neutralizers of authentic virions, these antibodies were
relatively poor neutralizers of pseudovirions. Conversely,
G131S.C2 appears to be able to neutralize pseudovirions
more efficiently than it did authentic virions.
To test the hypothesis that particle aggregation is an
important mechanism of neutralization for the two IgM MAbs
of the panel (G131S.G3 and H6.I2), monolayers of 293TTwere
exposed to HPV-11 pseudovirus at a low multiplicity of
infection for 1 h at 37 °C. Immediately after rinsing to remove
unattached pseudovirions, triplicate wells were treated with
medium containing serial dilutions of each MAb. Relative
levels of seAP in the supernatants were analyzed 3 days post-
infection. Consistent with the hypothesis being tested, H6.I2
lost 50% of its neutralizing ability when compared to the mean
change in EC90 concentrations measured for the other two
MAbs (both IgG) also targeting linear epitopes on the N-
terminus of L1. Similarly, G131S.G3 lost 86% of its neutraliz-
ing potential relative to the median change in EC90 concentra-
tions measured for the 7 divalent MAbs also targeting
conformation-sensitive epitopes.
Binding experiments using HPV-16 pseudovirions
In order to compare the neutralization efficiencies of MAbs
reactive with another HPV type, we measured the binding and
neutralization titers of supernatants from a large panel of HPV-
16 reactive MAbs using HPV-16 pseudovirions. Unexpectedly,
we found that under non-denaturing conditions many of the
MAbs (generated against L1-only VLPs) showed a relatively
poor ability to bind the pseudovirions (Fig. 3). In ELISA
binding assays utilizing three independent preparations of
infectious pseudovirions (produced in 293TT cells) or L1-only
VLPs (produced in insect cells) as antigen, several MAbs
showed high levels of binding in control wells containing VLPs,
but relatively poor binding to pseudovirions (e.g. H16.8B, .9A,
.11B, .15G, .B20, .H5, .I23, .J4, .O7, .S1, and .U4). By contrast,
eight other MAbs showed similar binding to the L1-only VLPs
and the L1/L2 pseudovirions. Capsomeric integrity was
demonstrated in each of these experiments by only backgroundFig. 2. Neutralization of HPV-11 virions and pseudovirions by specific MAbs.
(A) Neutralization of authentic HPV-11 virions. Bars represent the relative
neutralization efficiencies of the MAbs of the HPV-11 specific panel calculated
using half-maximal binding concentrations and RT-PCR neutralization titers
shown in Table 1. All neutralization efficiencies are shown standardized to that
of G131S.I1 which was assigned an efficiency of 1. (B) Bars indicate the mean
(±SE) MAb concentrations required to reduce successful pseudovirus infection
of 293TT cells (measured using seAP) by 50% (EC50), 90% (EC90), and 99%
(EC99) in 2 or more independent experiments performed for each MAb. In each
experiment duplicate or triplicate wells were utilized to evaluate each
concentration. Concentrations for H6.C6 and H6.E51 are shown using the
ordinate values shown on the right side. (C) Neutralization efficiencies
determined using pseudovirions were calculated for the EC50, EC90, and
EC99 endpoints. All efficiencies are standardized to those calculated for G131S.
I1 arbitrarily set at 1. For comparison, the antibodies are ordered to match the
sequence used in Fig. 2A.
Fig. 3. Binding of HPV-16 specific MAbs to pseudovirions vs. L1-only VLPs.
L1 surface epitope presentation was evaluated using three independent
preparations of pseudovirions. For each of three experiments, pseudovirions
and L1-only VLPs (produced in insect cells) were applied as antigen to wells of
a single 96-well microtiter plate overnight at 4 °C in PBS (pH 7.4). After
blocking, MAb supernatants were applied to wells at a dilution of 1:100 in
duplicate for each antigen. Final O.D. readings (405 nm) indicating binding to
pseudovirions or VLPs were obtained at a common time-point for each antigen
type. Means (±SE) for MAb binding to each antigen type were calculated. Data
are presented as pseudovirus binding as a percent of VLP binding. Underlined
MAbs target linear epitopes of L1.
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linear epitope of L1. Binding of the MAbs targeting linear
surface epitopes (underlined in Fig. 3) generally improved by
denaturation of the infectious pseudovirions (data not shown).
Sequencing the L1 ORF of the codon modified expression
plasmid p16L1H (Buck et al., 2004) confirmed that it encodes
an L1 molecule identical to that used as immunogen in the mice.
To further explore the epitopes present on particles produced
using this pseudovirus technology, we performed two parallel
transfections of 293TT monolayers with one receiving p16HL1,
p16HL2, and pYSEAP and a companion monolayer receiving
only p16HL1 and pYSEAP without the plasmid encoding L2Table 2
Neutralization efficiencies for L1-targeting MAbs reactive with HPV-16
MAb Location of
the targeted
epitope a
Isotype Binding half-Max
(VLPs) concentration
(dilution factor)
Binding half-m
(psV) concentra
(dilution factor)
H16.1A HI (FG) IgG2 3.3e−3±5.0e−5 1.5e−3±1.5e−4
H16.2F FG (HI) IgG2 1.4e−4±1.0e−5 4.3e−5±3.8e−5
H16.5A FG (HI) IgG2a 1.6e−4±2.5e−5 3.5e−5±5.0e−6
H16.6F FG (HI) IgG2a 1.9e−4±3.5e−5 4.0e−5±7.5e−6
H16.7E BC IgG2b 1.7e−4±5.0e−6 7.5e−5±4.5e−5
H16.E70 Unknown IgG2 6.3e−4±1.2e−4 1.5e−4±3.5e−5
H16.V5 FG (HI) IgG2b 5.5e−5±1.2e−5 5.0e−5±2.0e−5
H263.A2 HI (FG) unknown 1.4−3±2.5e−4 1.6e−4±2.0e−5
a Epitopes were mapped in previous studies— see Materials and methods section.
the loop influences the conformation of the MAb's epitope without directly interact
b Calculated using the half-maximal binding titers and EC50 neutralization titers det
defined in Formula #1 as the quotient of half-max and neutralization titer concentra
c Normalized to H16.E70 for ease of comparison. Higher efficiency ratios indicat
lesser degree of epitope saturation as determined by binding affinity.(p16HL2). As expected, no infectivity was detected in the
gradient fractions collected from the preparation omitting L2
and MAb binding to the L1-only particles indicated that these
particles were antigenically more similar to the L1-only VLPs
produced in insect cells (data not shown).
Using only the subset of hybridoma supernatants which
showed obvious binding to HPV-16 pseudovirions at a
concentration of 1:100, we compared the relative binding of
these MAbs to both L1-only VLPs and to pseudovirions (Table
2). Half-maximal binding concentrations for this subset of
MAbs ranged less than two logs for either antigen, and as
previously seen with HPV-11 particles, affinities for L1-only
VLPs and infectious pseudovirions were similar for each MAb
in this select panel indicating a high degree of antigenic
similarity between the two particle types at the corresponding
epitopes. The largest difference in MAb affinity to the two
particle types was seen with H263.A2 (∼9-fold reduced affinity
with pseudovirions).
Neutralization of HPV-16 pseudovirions
To examine the neutralizing ability of the MAb panel
generated against HPV-16 L1-only VLPs, infectious pseudovir-
ions were incubated with serial dilutions of hybridoma super-
natants prior to the inoculation of 293TT cells. For this assay,
successful neutralization was defined as the antibody titer
capable of blocking seAP secretion by 50% (EC50) of control
wells treated with the control antibody (Table 2). Most of the
antibodies in the HPV-16 panel bind directly to epitopes created
by loops FG and HI. All neutralizing MAbs were also able to
neutralize greater than 90% of pseudovirions preadsorbed to
293TT cells for 1 h at 37 °C when tested at a dilution of 1:200.
Not surprisingly, more limited experiments using the MAbs
which bound poorly to the HPV-16 pseudovirions in the native
ELISA (H16.J4, .U4, .9A, .8B, .11B, .15G, .C2, .H5, .I23, .O7,
and .S1) demonstrated that these antibodies were unable to
successfully neutralize these infectious particles in the standard
neutralization assay even at high concentrations such as 1:100
(data not shown).ax
tion
EC50
neutralization titer
(dilution factor)
Neutralization
efficiency
ratio b
Normalized
to H16.E70 c
Neutralizes
pre-attached
pseudovirus?
1.6e−4 9.4 25 Yes
6.8e−7 63 170 Yes
6.9e−6 5.1 13 Yes
4.4e−6 9.1 24 Yes
8.4e−5 0.89 2.3 Yes
4.0e−4 0.38 1 Yes
4.0e−7 125 330 Yes
3.9e−5 4.1 11 Yes
Loop structures are shown in parentheses, e.g. (HI), if available data suggest that
ing with the antibody.
ermined using pseudovirions. The neutralization efficiency ratio for eachMAb is
tions.
e the ability to neutralize a controlled number of HPV-16 pseudovirions with a
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suggest that many of the epitopes created by the FG and HI
loops of HPV-16 L1 are neutralization-sensitive. All MAbs
previously shown to bind directly to these loops on intertypic
hybrid VLPs were more potent neutralizers than the two
remaining antibodies, H16.E70 and H16.7E. The former MAb
binds a unique epitope created by residues 172-505, which is
disrupted by DE or FG loop replacements, by double mutant L1
proteins at residues 266 and 282, or at 353 and 475, and by
single mutations in L1 at multiple residues including 50, 266,
270, and 285 (Carter et al., 2003; Christensen et al., 2002;
Roden et al., 1997; White et al., 1999). H16.E70 has also been
shown to be more sensitive to VLP disassembly than H16.V5 or
H16.U4 (Slupetzky et al., 2001). In contrast to H16.E70, the
binding of H16.7E has been mapped convincingly to the BC
loop of HPV-16 L1 using intertypic hybrid VLPs (Christensen
et al., 2002).
Fab fragments can neutralize papillomavirus
While the effective neutralization of virions by multivalent
IgM (G131S.G3 and H6.I2) likely indicates that particle
aggregation is an effective mechanism of viral neutralization,
it is not known whether HPV neutralization can be achieved
without aggregation or L1 crosslinking. To discover if the
monovalent Fab fragments of neutralizing MAbs can also
neutralize infectious HPV particles, and with what efficiencies
relative to the divalent parental antibodies, we determined the
neutralization titers and half-max binding values for the Fab
fragments of selected MAbs (Table 3). The Fab fragments of
H11.B2, H11.H3, and H16.V5 neutralized infectious particles
with efficiencies similar to those of the parental antibody and
retained the ability to neutralize preadsorbed virions (HPV-11)
or pseudovirions (HPV-16). Reproducibly, however, the Fab
fragment of H11.F1 showed a much reduced ability to
neutralize HPV-11 virions although it bound capsids with an
affinity similar to the parental antibody. Fab fragments of H6.C6
could not accomplish complete neutralization in the nested RT-Table 3
Neutralization efficiencies for selected divalent IgG and their monovalent Fab fragm
MAb Location of the
targeted epitope
Isotype Binding half-max
concentration (nM) a
H6.C6 N-term linear site IgG2a 4.0
Fab 120
H11.B2 DE IgG2b 0.48
Fab 6.7
H11.F1 DE IgG2a 0.8
Fab 0.52
H11.H3 HI IgG2b 0.22
Fab 21
H16.V5 FG (HI) IgG2b 0.41
Fab 4.6
NT = not tested.
a Calculated using the half-maximal binding concentrations determined by ELIS
together in the same experiments.
b Values determined by independent experiments evaluating the minimal MAb or
when measured by nested RT-PCR (H6.C6, H11.B2, H11.F1, and H11.H3) or
pseudovirions (EC50) when measured by levels of seAP (H16.V5).PCR assay even at a concentration of 200 μM. However, QRT-
PCR analysis of viral E1^E4 transcripts showed that H6.C6 Fab
fragments at this high concentration had neutralized about 50%
of input virions.
Neutralization of virions by scFv fusion proteins
The discovery that monovalent Fabs could neutralize HPV-
11 led us to question whether neutralization might also be
accomplished by recombinant scFv. To test this possibility, the
variable fragments of both heavy and light chains were cloned
for selected antibodies (Materials and methods). Refolded scFvs
(produced in insect cells) were examined for specific binding to
VLPs by ELISA. The scFv made from H11.B2 (scB2) bound
HPV-11 VLPs much better than the scFv made from H11.H3
(scH3) (data not shown). Neutralization experiments using the
refolded scB2 showed unsuccessful neutralization when
assayed by nested RT-PCR. However, subsequent analysis by
QRT-PCR revealed that a high degree of neutralization could be
attained with this recombinant protein with a neutralization
efficiency comparable to that of the monovalent H11.B2 Fab
fragment (Fig. 4). Recombinant scB2-GFP, scH3, and scH3-
GFP were also shown by QRT-PCR to have neutralizing activity
with HPV-11 virions (data not shown).
To improve yield and eliminate the refolding process, the
scB2, scB2-GFP, scH3, and scH3-GFP sequences were cloned
into plasmid pAcSecG2T in order to generate a secreted
fusion protein with an epitope tag (glutathione S-transferase,
GST) at the NH2-terminus of the scFv (creating GST-scB2,
GST-scB2-GFP, etc.). Both Sf21 and High 5 cells infected
with these recombinant baculoviruses secreted high levels of
scFv for at least 1 week (data not shown). As we had
observed previously with the non-secreted construct, scB2
proteins showed stronger binding than the scH3 counterparts
when assayed by ELISA. Interestingly, HPV-11 virions
preincubated with insect cell supernatants containing GST-
scB2 or GST-scB2-GFP were completely neutralized as
assayed by nested RT-PCR and considerable evidence ofents
Neutralization
titer (nM) b
Neutralization efficiency
relative to parental MAb
Neutralizes
pre-attached particles?
533 1 Yes
>2e5 <0.08 NT
4.17 1 Yes
200 0.31 Yes
16.7 1 Yes
3200 0.0034 Yes
0.25 1 Yes
25 0.95 Yes
0.16 1 Yes
9.2 0.2 NT
A using VLPs as antigen. Binding of parental IgG and Fabs were evaluated
Fab concentration accomplishing the complete neutralization of HPV-11 virions
the concentration required for the neutralization of 50% of input HPV-16
Fig. 4. Neutralization of HPV-11 virions by scFv of H11.B2. (A) HPV-11 virions
were preincubated with H11.B2 Fab fragments or with the H11.B2 scFv (scB2)
prior to infecting A431 cells (150 particles/cell). Four days post-infection, total
RNA was assayed for the presence of E1^E4 transcripts using QRT-PCR. (B)
Half-maximal binding concentrations were determined by ELISA using HPV-11
L1-only VLPs as antigen. HPV-11 neutralization titers (as EC50) were
determined using QRT-PCR assay of E1^E4 viral transcripts. Neutralization
efficiencies were calculated with Formula #1.
Fig. 5. Neutralization of HPV-11 virions by secreted scFv. (A) HPV-11 virions
were incubated with various High 5 supernatants prior to infection of A431 cells.
Virions were incubated with spent medium of either uninfected cells (Mock) or
cells infected with recombinant baculoviruses containing genes for secreted
GST-scFv fusion proteins. E1^E4 transcripts in total RNAwere assayed 4 days
post-infection using nested RT-PCR. Similar results were seen with supernatants
of infected Sf9 cells (not shown). (B) High 5 cell supernatants containing
secreted GST-scFv fusion proteins were added to DMEM (at 1:12.5) and layered
over rinsed A431 monolayers inoculated 12 h previously with HPV-11 virions.
Medium was replaced again after 6 h. Infection was assayed 4 days post-
infection by QRT-PCR. GST-B1.A1 is a non-functional scFv for the BPV-1
specific antibody B1.A1 and was used here as a negative control.
441T.D. Culp et al. / Virology 361 (2007) 435–446neutralization was seen when treatment with these fusion
proteins followed viral adsorption (Fig. 5).
Discussion
It is generally assumed that humoral immunity can largely
protect against type-specific papillomavirus infections. Experi-
ments using in vivo infection models (Breitburd et al., 1995;
Christensen et al., 1996c; Kirnbauer et al., 1996; Suzich et al.,
1995) and results from clinical trials (Billich, 2003; Koutsky et
al., 2002) have shown that protection correlates well with
specific antibody responses. While VLP vaccines typically
induce a high titer serum antibody response immediately
following immunization, the duration of protection provided by
a standard vaccine regimen remains unknown. Improved VLP
vaccines would promote the production of neutralizing
antibodies targeting multiple HPV types, conserved epitopes,
and epitopes most critical to viral adsorption, entry, and
trafficking.
The purpose of these studies was to probe for potentially
“neutralization-sensitive” L1 epitopes and surface structures
using two large panels of MAbs. The number of capsid binding
events possible for a given MAb is influenced by several factors
including the exposure of target epitope and the antibody
isotype. Because this value for each epitope-MAb pair is
difficult to determine, and of limited clinical importance, an
analysis of neutralization based upon epitope saturation was
performed.Even when normalized for epitope saturation, it is apparent
that individual MAbs are not equal in their abilities to neutralize
virus particles. In analyzing the data we assumed that: (i)
multiple epitopes are likely to exist on each hypervariable loop,
(ii) a binding event at a given epitope may inhibit the viral
particle more or less than a binding event at a proximal epitope,
and (iii) the paratope of each antibody is unique making each
antibody–epitope interaction also unique. With at least one
exception, our data suggest that antibodies directly interacting
with the FG and HI loops are likely to be potent neutralizing
antibodies. This finding could indicate that these two hyperva-
riable loops are dense in “neutralization-sensitive” epitopes.
A previous study using HPV-16 positive human sera
suggested that the FG and HI loops contain epitopes commonly
targeted by neutralizing antibodies (Carter et al., 2006).
Similarly, H16.V5, an MAb targeting an epitope on the FG
loop of HPV-16 L1, was previously found to block binding of
the majority of HPV-16 reactive antibody in human serum
(Wang et al., 1997). These studies may indicate that vaccination
with wild type HPV-16 VLPs is already optimal for generating
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genotype.
All the MAbs in our panels which were able to bind
infectious HPV particles were also able to block infection by
those particles using a specified endpoint. Two MAbs (H6.C6
and H11.A3.2) which were previously characterized as non-
neutralizing when tested as supernatants (Christensen et al.,
1994a, 1994b, 1996b) were shown here to be capable of
complete neutralization of both HPV-11 virions and pseudovir-
ions. While one MAb (H6.E51) was incapable of complete
neutralization with the stringent endpoint of the virion nested
RT-PCR assay, this same antibody neutralized >99% of
infectious particles in the pseudovirion assay. The reality of
non-neutralizing antibodies/epitopes with virus models has
been questioned (Klasse and Sattentau, 2002). Given the
structure of HPV capsids, it seems likely that a high degree of
saturation of any individual L1 epitope can accomplish HPV
neutralization (Booy et al., 1998). Our data suggest that surface-
exposed epitopes termed “non-neutralizing” might more
accurately be termed “neutralization-insensitive” as the former
terminology may unduly generalize experimental results with-
out sufficient regard to antibody titer and the endpoint of the
particular infection assay.
Due to the challenge of obtaining large numbers of authentic
virions, we utilized VLPs and pseudovirions for all the binding
studies. In the case of HPV-11 particles, we saw no strong
evidence of antigenic differences between L1-only VLPs and
infectious pseudovirions. While we assumed that HPV-11
pseudovirions more accurately model epitopes on the surface of
authentic virions, this assumption remains untested. Conflicting
results with a subset of MAbs in our HPV-11 neutralization
experiments (virion vs. pseudovirion neutralization) could
indicate that considerable antigenic differences between these
particle types exist at a subset of epitopes. However, intrinsic
differences between the two infection assays (e.g. cell lines and
endpoints) complicate this analysis.
Using the large HPV-16 reactive antibody panel, we found
evidence of differences in the surface epitopes of HPV-16
pseudovirions and VLPs (Table 2). Several MAbs showed
strong reactivity to HPV-16 L1 VLPs but only minimal binding
to infectious pseudovirions. These latter particles include the
minor capsid protein, L2, and encapsidate a 6 kB reporter
plasmid. Our data confirm that L2 facilitates the production of
infectious particles (Roden et al., 1996) and further suggest that
the presence of L2 and/or encapsidated DNA alters surface
exposure of a subset of L1 epitopes (Fligge et al., 2001).
Accordingly, we predict that pseudovirions would antigenically
resemble virions more closely than L1-only VLPs. Our studies
demonstrate the value and potential of using large panels of
antibodies to probe for variations in the surface structure of
these different particles.
The relatively weak binding of H16.I23, H16.J4, and H16.
U4 to pseudovirions was particularly interesting because these
antibodies have been shown, at high antibody concentrations, to
be capable of neutralizing pseudovirions produced by alternate
technologies (Combita et al., 2002; Roden et al., 1997). We saw
little evidence that these MAbs could bind or neutralizeindependent preps of HPV-16 pseudovirions even at super-
natant concentrations as high as 1:50. H16.I23 binds a linear
epitope within residues 111-130 (adjacent to the DE loop) while
H16.J4 binds a linear epitope in residues 260-281 (in the FG
loop) (Dillner et al., 1990). Both H16.I23 and H16.J4 were
previously shown to bind VLPs of dissimilar genotypes and to
cross-neutralize pseudovirions (Christensen et al., 1996a;
Combita et al., 2002). Using non-denaturing conditions, both
the H16.I23 and H16.J4 epitopes are largely unavailable for
binding at the surface of our pseudovirions. H16.U4 binds a
conformation-dependent epitope on the COOH-terminus of
HPV-16 L1 that is surface-exposed on VLPs (Carter et al.,
2003), but found to be non-neutralizing at high concentrations
using authentic HPV-16 virions (White et al., 1999). These
findings might indicate that the pseudovirions produced in
293TT cells more closely model the surface epitopes of
authentic HPV-16 virions than do L1-only VLPs and that
pseudovirus particles made using different eukaryotic systems
may be antigenically distinct at a subset of surface epitopes.
Unfortunately, none of the MAbs targeting linear epitopes
bound to intact HPV-16 pseudovirions so it remains untested
whether antibodies binding linear epitopes on HPV-16 can
interrupt the early events of infection.
H16.7E, which binds the BC loop of HPV-16 on intertypic
VLPs, had one of the lowest neutralization efficiencies,
indicating that this MAb requires a higher degree of epitope
saturation to neutralize pseudovirions. Interestingly, we have
unpublished data demonstrating that H16.7E is the most
efficient MAb tested for blocking VLP attachment to both the
membrane-associated receptors and to laminin-5 in the extra-
cellular matrix (Culp et al., 2006a, 2006b). These results may
indicate that the blocking of viral attachment is an important
method of neutralization for this particular MAb.
Parental MAbs, Fab fragments, and scFv were utilized to
compare the effectiveness of monovalent and divalent binding
events on interrupting early events in viral infection. Data
derived with H11.B2, H11.H3, and H16.V5 and their Fab
fragments show that equivalent saturation of each correspond-
ing epitope results in comparable neutralization regardless of
the valency of the binding molecule. This finding suggests that
the parental antibodies, each targeting a different loop of L1,
can neutralize virions by a mechanism independent of particle
aggregation and L1 crosslinking.
In other virus models it has been shown that a subset of
Fab fragments accomplish neutralization by a different
mechanism than the parental IgG (Edwards and Dimmock,
2000, 2001; McInerney et al., 1997). This appears to be true
for the Fab fragment of H11.F1 which had a half-maximal
binding concentration comparable to the parental IgG but was
relatively impotent in its ability to neutralize virions. In
contrast to H11.B2, which also binds an epitope on the DE
loop, the neutralizing potency of intact H11.F1 is likely to
require L1 crosslinking.
Each MAb capable of binding to HPV pseudovirions
demonstrated successful particle neutralization. These results
do not support the hypothesis that non-neutralizing epitopes
are present on the surface of HPV virions. However, our data
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tion by a substantially lower degree of epitope saturation than
other MAbs. Additional studies to map and characterize
“sensitive” epitopes on HPV capsids may improve our
understanding of virus–host interactions and provide informa-
tion helpful in the development of more efficacious prophy-
lactic vaccines.
Materials and methods
Cells and cell culture
A431 cells (human vulvar carcinoma) were cultured and
infected in DMEM supplemented with 5% FBS. 293TT cells
(human kidney) which show high expression of SV40 large T
antigen (Buck et al., 2004) were cultured in DMEM
supplemented with 10% FBS and hygromycin (400 μg/ml).
These cells were infected in DMEM (10% FBS) lacking both
phenol red and hygromycin (“infection medium”).
MAbs and Fab fragments
Mapping studies have been previously described for: H11.
B2, H11.F1, and H11.G5 (Ludmerer et al., 1996, 1997), H11.
A3.2 (Ludmerer et al., 1996, 2000), H11.H3, G131S.C2,
G131S.G3, and G131S.I1 (Ludmerer et al., 2000), H16.1A,
H16.2F, H16.5A, H16.6F, H16.7E, H16.8B, H16.9A, H16.11B,
H16.15G, and H263.A2 (Christensen et al., 2002), H16.B20,
H16.C2, H16.D9, H16.H5, H16.I23, H16.J4, H16.L4, H16.O7,
and H16.S1 (Christensen et al., 1996a), H16.U4 (Carter et al.,
2003), and H16.V5 (Carter et al., 2003; Christensen et al.,
2002). Numerous studies have provided information on the
binding epitope of H16.E70 (Carter et al., 2003; Christensen et
al., 2002; Roden et al., 1997; Sadeyen et al., 2003; Slupetzky et
al., 2001; White et al., 1999). H6.C6, H6.E51, and H6.I2 bind a
linear epitope in the first 88 residues of L1 which does not
involve the residues of the BC loop (unpublished data). For
purified MAbs against HPV-11 and for H16.V5, ascites
produced in BALB/C mice were purified using Immobilized
Protein A Columns (Pierce). Eluted antibody was dialyzed into
PBS (pH 7.4) and the protein concentration determined using
A280. For generation of Fab fragments, purified antibody was
digested with papain and isolated using the ImmunoPure Fab
Preparation Kit (Pierce) according to manufacturer's
recommendations.
HPV particles
Authentic HPV-11 virions were obtained from infected
xenografts grown in immunocompromised mice as previously
described (Kreider et al., 1987). HPV-11 and HPV-16
pseudovirions were produced in monolayer cell culture using
the method previously described (Buck et al., 2004). Briefly,
293 cells selected for high SV40 large T antigen expression
(293TT cells) were transfected simultaneously with plasmids
expressing codon-modified L1 and L2 together with a plasmid
expressing secreted alkaline phosphatase (pYSEAP) as areporter plasmid or “pseudogenome”. Two days post-transfec-
tion, the cells were lysed with Brij-58 to release the L1/L2
particles encapsidating the reporter plasmid. Cell lysates were
treated with DNases to destroy non-encapsidated DNA prior to
purification using densitometric fractionation on an Optiprep
gradient (Accurate Chemical). Following analysis of gradient
fractions by ELISA and immunoblotting to detect capsid
proteins, the infectivity and neutralization of infectivity by
capsid-specific antibodies were analyzed using an in vitro
infection assay. Briefly, 293TT cells seeded into 96-well
culture plates were infected with material from capsid-positive
fractions incubated±antibodies. Three days post-infection,
samples of spent media were transferred to a 96-well
microtiter plate and assayed for relative seAP levels using a
standard colorimetric assay (p-nitrophenyl phosphate). VLPs
were produced using insect cells infected with recombinant
baculoviruses and purified using CsCl gradients as previously
described (Christensen et al., 1994a,1994b) or by the
transfection of 293TT cells with plasmids expressing HPV
capsid proteins. In the case of the latter, capsids were
harvested, matured, and purified using the same protocol as
used for pseudovirions described above.
In vitro infection assay
HPV-11 virions (1.6×108 particles=approximately 150
particles/cell) were incubated with dilutions of MAbs, Fab
fragments, or scFv fusion proteins for 1 h at 37 °C in a final
volume of 100 μl (PBS, pH 7.4). The mixture was then added to
monolayers of A431 cells in 1 ml DMEM (5% FBS). Four days
post-infection, monolayers were lysed and RNA was isolated
using TRIzol (Invitrogen) per manufacturer's suggested proto-
col. Nested RT-PCR was performed for amplification of viral
E1^E4 transcripts and β-actin transcripts using the GeneAmp
RNA PCR Core Kit (Applied Biosystems) with the primers
(Ludmerer et al., 2000) and method previously described (Culp
and Christensen, 2003). QRT-PCR for E1^E4 and TBP
transcripts was performed using the Quantitect Probe RT-PCR
kit with the primers, probes, and method previously described
(Culp and Christensen, 2003). For pseudovirus neutralization
experiments, a predetermined infectious dose of HPV-11 or
HPV-16 pseudovirions (particle count undetermined) was
incubated at 37 °C with a dilution of purified MAb (HPV-11
series) or hybridoma supernatant (HPV-16 series) in a total
volume of 100 μl per well (remaining volume composed of
infection medium). One hour later, the pseudovirion–MAb
mixture was added to replicate wells containing 293TT cells.
Three days post-infection, an aliquot of the spent medium in
each well was transferred to a 96-well microtiter plate and
combined with p-nitrophenyl phosphate. Colorimetric assay
was then performed on a microtiter plate reader at a wavelength
of 405 nm.
ELISA-based calculation of binding affinity
Binding affinities for individual MAbs were measured using
L1-only VLPs or L1/L2 pseudovirions adhered to 96-well
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with 5% nonfat dry milk containing 0.05% Span-20 (Sigma),
and all serial dilutions of antibodies were made in blocking
solution. Bound MAbs were detected with AP-conjugated anti-
mouse antibodies using p-nitrophenyl phosphate.
Cloning of single-chain variable fragments (scFv)
RNA from MAb hybridoma cell lines was isolated using
TRIzol (Invitrogen). The variable coding sequences of the
MAbs were fused using a (Gly5Ser)3 linker. In some cases, we
also generated fusion proteins with the scFv and green
fluorescent protein (GFP). Heavy chain variable sequences
(VH) were cloned at the NH2-end of the scFv using the sense
primer 5′-ATAGTCTAGACCGCCATGGATGTGCATCTT-
CAGGAGTCGGGACCTG-3′ and the antisense primer 5′-
ACCTGGATCCGCCTCCGCCTGATGGATAGACA-
GATGGGGGTGTCGTTTTGGC-3′ which includes 1/3 of the
(Gly4Ser)3 linker. VH amplicons were cloned into pUC19 using
XbaI and BamHI and sequenced at the Penn State College of
Medicine Core Facility. Light chain variable (VL) sequences
were cloned using a degenerate sense primer 5′-TCCAG-
GATCCGGTGGCGGTGGATCTGGAGGTGGCGGAAGC-
GACATTGTGMTGACCCARTCTC which includes 2/3 of the
(Gly4Ser)3 linker with the antisense primer 5′-TACAGAA-
TTCGCTGCAGCATGGATACAGTTGGTGCAGCAT-
CAGCCCG-3′ which includes an (Ala)3 linker. VL amplicons
were cloned into pUC19 at BamHI and EcoRI and sequenced.
Legitimate VL sequences were cloned 3′ of legitimate VH
sequences using BamHI and EcoRI. The coding sequence for
enhanced green fluorescence protein (GFP) was subcloned out of
a separate vector using the sense primer 5′-ATTACAGAATTC-
CACCGAGTGGGGCCCTTTCGAAGTTAGCAGCCGC-
CATGGTGAGCAAGGGCGAGGAGCTGTTCACCGG-3′
and the antisense primer 5′-ATTACAGAATTCGTTTAAACT-
TAAAGCTTGTACAGCTCGTCCATGCCG-3′. The sequenced
GFP gene was then cloned 3′ of the VH VL sequence using
EcoRI.
To prepare recombinant baculoviruses using pBlueBac 4.5/
His (Invitrogen) encoding scFv lacking the GFP fusion, VHVL
sequences were subcloned into this expression vector from the
pUC19-VHVL-GFP cloning vectors using XbaI and BstBI. For
the scFv-GFP fusion constructs, the subcloning was performed
using XbaI and HindIII.
To prepare the cloned VHVL-GFP sequences for additional
vectors, we first removed the BamHI site within the (Gly4Ser)3
linker and removed the ATG at the 5′ end of GFP by site-
directed mutagenesis. Restriction sites were added to the 5′ end
of the VHVL-GFP sequences by PCR using the sense primer 5′-
ATAGAGCTCGGATCCAAGGTACCACTCGAGGCCGC-
CATGGATGTGCATCTTCAGG-3′. Restriction sites were
added to the 3′ end of the VHVL sequence using the antisense
primer 5′-TAGCTGTCGACTAGGATCCAGCGGCCG-
CAATTCGCTGCAGCATGGATACAGTTGG-3′ and to the
3′ end of the entire VHVL-GFP sequences with the antisense
primer 5′-ATAGCTGTCGACTAGGATCCAGCGGCCG-
CAAGCTTGTACAGCTCGTCCATGCCAA-3′. After sequen-cing, the amended VHVL and VHVL-GFP sequences were
subcloned into pAcSecG2T (Pharmingen) using BamHI.
Expression of scFv fusion proteins
For intracellular His-tagged scFv fusion proteins, we
produced recombinant baculoviruses in Sf9 insect cells using
scFv sequences subcloned into pBlueBac 4.5/His and Bac-N-
Blue DNA (Invitrogen) according to manufacturer's recom-
mendation. Recombinant baculovirus in infected Sf9 super-
natants was used to infect High 5 cells at high m.o.i. for the
production of scFv. As evident from the fluorescence seen in
High 5 cells infected with scFv-GFP constructs, high amounts
of fusion proteins were present in cells but localized in inclusion
bodies. Using several non-denaturing cell lysis protocols, we
were unsuccessful in solubilizing the fusion proteins. As an
alternative approach, transduced insect cells were lysed with
6 M guanidine–HCl, 50 mM sodium phosphate, 300 mM NaCl
(pH 7) followed by a slow and stepwise removal of guanidine
by dialysis. His-tagged scFv fusion proteins were then purified
using a Talon resin column (BD Biosciences) and analyzed by
ELISA or immunoblot (data not shown).
For secreted glutathione S-transferase (GST)-scFv fusion
proteins, recombinant baculoviruses were produced with scFv
subcloned into the pAcSecG2T vector using Sf9 cells and the
BaculoGold transfection kit (Pharmingen). Supernatants con-
taining recombinant baculoviruses were used to infect Sf9 cells
or High 5 cells. Supernatants were collected at various time-
points and analyzed for the presence of GST-fusion proteins by
ELISA and immunoblot (data not shown).References
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